Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Censavudine - Transposon Therapeutics

Next Previous
Drug Profile

Censavudine - Transposon Therapeutics

Alternative Names: 4'-Ethynyl-d4T - Transposon Therapeutics; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; OBP-601; TPN-101

Latest Information Update: 14 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kagoshima University; Showa University; Yale University
  • Developer Oncolys BioPharma; Transposon Therapeutics
  • Class Antidementias; Antivirals; Furans; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Aicardi-Goutieres syndrome; Amyotrophic lateral sclerosis; Frontotemporal dementia; Progressive supranuclear palsy
  • Discontinued HIV-1 infections

Most Recent Events

  • 09 Jul 2025 Transposon Therapeutics plans to initiate a phase II trial for Alzheimer's disease in fourth quarter of 2025
  • 28 May 2025 Transposon Therapeutics in collaboration with Northeast ALS Consortium plans a HEALEY ALS platform trial in Amyotrophic lateral sclerosis in the fourth quarter of 2025
  • 24 Jul 2024 Efficacy and adverse event data from phase II trial for Amyotrophic Lateral Sclerosis and Frontotemporal dementia released by Transposon Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top